Radiotherapy & Oncology
Volume 93, Issue 2 , Pages 192-196 , November 2009

Palliative prostate radiotherapy for symptomatic advanced prostate cancer

Received 4 June 2008 ,Revised 16 April 2009 ,Accepted 18 April 2009.

References 

  1. NICE Clinical Guideline: prostate cancer. London: National Collaborating Centre for Cancer; 2008.
  2. Toms JR. Cancerstats monograph. London: Cancer Research UK; 2004.
  3. Ross RW, Xie W, Regan MM, et al. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect. Cancer. 2008;112:1247–1253
  4. Heidenreich A, Aus G, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol. 2008;53:68–80
  5. Hindson B, Turner S, Do V. Palliative radiation therapy for localized prostate symptoms in hormone refractory prostate cancer. Australas Radiol. 2007;51:584–588
  6. Lankford SP, Pollack A, Zagars GK. Radiotherapy for regionally localized hormone refractory prostate cancer. Int J Radiat Oncol Biol Phys. 1995;33:907–912
  7. Nakamura K, Teshima T, Takahashi Y, et al. Radiotherapy for localized hormone-refractory prostate cancer in Japan. Anticancer Res. 2004;24:3141–3145
  8. Furuya Y, Akakura K, Akimoto S, Ichikawa T, Ito H. Radiotherapy for local progression in patients with hormone-refractory prostate cancer. Int J Urol. 1999;6:187–191
  9. Kawakami S, Kawai T, Yonese J, Yamauchi T, Ishibashi K, Ueda T. Palliative radiotherapy for local progression of hormone refractory stage D2 prostate cancer. Nippon Hinyokika Gakkai Zasshi. 1993;84:1681–1684
  10. Hernes EH, Linja M, Fossa SD, et al. Hormone-resistant prostate cancer with symptomatic pelvic tumours: patient survival and prognostic factors. BJU Int. 2000;86:240–247
  11. Clarke NW. The management of hormone-relapsed prostate cancer. BJU Int. 2003;92:860–868
  12. Mazur AW, Thompson IM. Efficacy and morbidity of channel TURP. Urology. 1991;38:526–528
  13. Crain DS, Amling CL, Kane CJ. Palliative transurethral prostate resection for bladder outlet obstruction in patients with locally advanced prostate cancer. J Urol. 2004;171:668–671
  14. Gnanapragasam VJ, Kumar V, Langton D, Pickard RS, Leung HY. Outcome of transurethral prostatectomy for the palliative management of lower urinary tract symptoms in men with prostate cancer. Int J Urol. 2006;13:711–715
  15. Morioka M, Kobayashi T, Furukawa Y, et al. Prostate-specific antigen levels and prognosis in patients with hormone-refractory prostate cancer treated with low-dose dexamethasone. Urol Int. 2002;68:10–15
  16. Nishimura K, Nonomura N, Yasunaga Y, et al. Low doses of oral dexamethasone for hormone-refractory prostate carcinoma. Cancer. 2000;89:2570–2576
  17. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14:1756–1764
  18. Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol. 1999;17:2506–2513
  19. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–1512
  20. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–1520

PII: S0167-8140(09)00191-1

doi: 10.1016/j.radonc.2009.04.017

Radiotherapy & Oncology
Volume 93, Issue 2 , Pages 192-196 , November 2009

Article Tools

* Image Usage & Resolution